A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants

GSK3640254 is a next-generation maturation inhibitor that would likely be combined with standard antiretroviral agents to form a regimen of ≥2 fully active classes. This phase I, open-label, 2-period, 1-way study assessed potential pharmacokinetic (PK) interactions between GSK3640254 and tenofovir a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pene Dumitrescu, Teodora, Joshi, Samit R., Xu, Jianfeng, Zhan, Joyce, Johnson, Mark, Butcher, Laurie, Zimmerman, Eric, Webster, Lindsey, Davidson, Antonia M., Lataillade, Max, Min, Sherene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316023/
https://www.ncbi.nlm.nih.gov/pubmed/33753329
http://dx.doi.org/10.1128/AAC.02173-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316023/
https://www.ncbi.nlm.nih.gov/pubmed/33753329
http://dx.doi.org/10.1128/AAC.02173-20

Ejemplares similares